Strategy in I.V.

Marketing the I.V. drug throughout the world

The medicinal product “Methylthioninium Chloride Proveblue 5mg/ml solution for injection” developed by Provepharm was remarkably found eligible for submission of an application for a centralised European marketing authorisation as antidote against maethemoglobinemia.

The European authorisation was granted in May 2011.

This marketing authorization is the stepping stone of Provepharm’s global strategy to reset Methylene Blue Injection as a drug through :

  • The registration of Methylthioninium Chloride Proveblue in the United States, Japan and emerging countries
  • The extension of registered indications for Methylthioninium Chloride Proveblue,so that the drug with improved benefit/risk ratio is made available to the largest possible number of patients worldwide. The I.V. drug Methylthioninium Chloride Proveblue is sold through licensed pharmaceutical distributors.